Lisata Therapeutics (LSTA) 10-Q 5 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information Document - shares	9 Months Ended
	Sep. 30, 2015	Nov. 04, 2015
Document Information [Line Items]
Entity Registrant Name	Caladrius Biosciences, Inc.
Entity Central Index Key	320,017
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		55,373,251

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 24,042,699	$ 19,174,061
Marketable securities	5,349,396	7,080,053
Accounts receivable, net of allowance for doubtful accounts of $381,588 and $385,362 at September 30, 2015 and December 31, 2014, respectively	2,299,817	3,111,274
Deferred costs	3,348,619	2,566,989
Prepaid expenses and other current assets	3,441,156	4,349,167
Total current assets	38,481,687	36,281,544
Property, plant and equipment, net	17,095,395	15,960,731
Goodwill	25,209,336	25,209,336
Intangible assets, net	37,706,498	47,560,406
Other assets	1,209,632	1,263,375
Total assets	119,702,548	126,275,392
Current Liabilities
Accounts payable	2,467,049	5,661,173
Accrued liabilities	8,011,205	4,322,901
Long-term debt, current	2,751,425	1,109,612
Notes payable, current	1,012,189	816,776
Unearned revenues	5,498,074	4,334,120
Total current liabilities	19,739,942	16,244,582
Long-term Liabilities
Deferred income taxes	14,566,093	18,176,190
Notes payable	814,062	825,897
Long-term debt	12,248,575	13,890,388
Acquisition-related contingent consideration	13,880,000	18,260,000
Other long-term liabilities	3,457,457	804,546
Total liabilities	$ 64,706,129	$ 68,201,603
Commitments and Contingencies
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares; Series B convertible redeemable preferred stock liquidation value, 0.01 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2015 and December 31, 2014	$ 100	$ 100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 55,497,240 and 36,783,857 shares, at September 30, 2015 and December 31, 2014, respectively	55,497	36,784
Additional paid-in capital	395,014,267	350,428,903
Treasury stock, at cost	(705,742)	(705,742)
Accumulated deficit	(338,935,644)	(291,246,538)
Accumulated other comprehensive income	878	1,329
Total Caladrius Biosciences, Inc. stockholders' equity	55,429,356	58,514,836
Noncontrolling interests	(432,937)	(441,047)
Total equity	54,996,419	58,073,789
Liabilities and Equity, Total	$ 119,702,548	$ 126,275,392

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Preferred Stock, Shares Outstanding	10,000	10,000
Common Stock, Par Value	$ 0.001	$ 0.001
Accounts receivable trade, net of allowance for doubtful accounts	$ 381,588	$ 385,362
Preferred Stock, authorized	20,000,000	20,000,000
Common Stock, Shares, Outstanding	55,497,240	36,783,857
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	55,497,240	36,783,857
Preferred stock, shares designated	825,000	825,000
Preferred stock, issued	10,000	10,000
Preferred stock, Series B convertible redeemable preferred stock liquidation value, share of common stock	0.01	0.01
Preferred stock, par value	$ 0.01	$ 0.01

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues	$ 5,888,450	$ 4,117,783	$ 14,927,691	$ 12,662,290
Cost of revenues	4,808,679	4,012,369	13,976,087	11,515,168
Research and development	6,315,613	8,469,623	20,719,989	19,024,728
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	0	0	9,400,000	0
Selling, general, and administrative	5,147,166	7,894,291	24,971,438	24,310,324
Total operating costs and expenses	16,271,458	20,376,283	69,067,514	54,850,220
Operating loss	(10,383,008)	(16,258,500)	(54,139,823)	(42,187,930)
Other (expense) income:
Other (expense) income, net	(410,233)	(687,280)	4,398,585	(1,062,568)
Interest expense	(552,983)	(183,477)	(1,651,222)	(383,539)
Nonoperating Income (Expense), Total	(963,216)	(870,757)	2,747,363	(1,446,107)
Loss before provision (benefit) for income taxes and noncontrolling interests	(11,346,224)	(17,129,257)	(51,392,460)	(43,634,037)
Provision (benefit) for income taxes	46,633	47,387	(3,610,097)	142,183
Net loss	(11,392,857)	(17,176,644)	(47,782,363)	(43,776,220)
Less - loss attributable to noncontrolling interests	(16,907)	(202,375)	(93,257)	(514,877)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (11,375,950)	$ (16,974,269)	$ (47,689,106)	$ (43,261,343)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$ (0.21)	$ (0.48)	$ (1.04)	$ (1.37)
Weighted average common shares outstanding	55,239,119	35,053,218	45,867,567	31,663,221

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Net loss	$ (11,392,857)	$ (17,176,644)	$ (47,782,363)	$ (43,776,220)
Available for sale securities - net unrealized loss	(988)	(886)	(451)	112
Total other comprehensive loss	(988)	(886)	(451)	112
Comprehensive loss	(11,393,845)	(17,177,530)	(47,782,814)	(43,776,108)
Comprehensive loss attributable to noncontrolling interests	(16,908)	(202,375)	(93,257)	(514,877)
Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders	$ (11,376,937)	$ (16,975,155)	$ (47,689,557)	$ (43,261,231)

Consolidated Statements of Equi

Consolidated Statements of Equity - 9 months ended Sep. 30, 2015 - USD ($)	Total	Total NeoStem, Inc. Shareholders' Equity [Member]	Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]
Beginning Balance (shares) at Dec. 31, 2014			10,000	36,783,857
Beginning Balance at Dec. 31, 2014	$ 58,073,789	$ 58,514,836	$ 100	$ 36,784	$ 350,428,903	$ 1,329	$ (291,246,538)	$ (705,742)	$ (441,047)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(47,782,363)	(47,689,106)					(47,689,106)		(93,257)
Unrealized gain on marketable securities	(451)	(451)				(451)
Share-based compensation (in shares)				811,835
Share-based compensation	8,568,605	8,568,605		$ 812	8,567,793
Stock Issued During Period, Shares, New Issues				17,901,548
Net proceeds from issuance of common stock	36,136,839	36,136,839		$ 17,901	36,118,938
Proceeds from exercise of options	0
Change in Ownership in Subsidiary	0	(101,367)			(101,367)				101,367
Ending Balance at Sep. 30, 2015	$ 54,996,419	$ 55,429,356	$ 100	$ 55,497	$ 395,014,267	$ 878	$ (338,935,644)	$ (705,742)	$ (432,937)
Ending Balance (shares) at Sep. 30, 2015			10,000	55,497,240

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Payments to Acquire Marketable Securities	$ 6,081,900	$ 920,329
Cash flows from operating activities:
Net loss	(47,782,363)	(43,776,220)
Adjustments to reconcile net loss to net cash used in operating activities:
Equity-based compensation expense	8,568,605	8,941,452
Depreciation and amortization	1,893,028	1,578,334
Changes in fair value of derivative liability	0	23,175
Change in acquisition-related contingent consideration	(4,380,000)	1,090,000
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	9,400,000	0
Bad debt recovery	(3,774)	(5,763)
Deferred income taxes	(3,610,097)	142,183
Accretion Expense	77,577	7,329
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	908,011	(2,795,249)
Accounts receivable	815,231	(177,162)
Deferred costs	(781,629)	(872,079)
Unearned revenues	1,163,954	1,823,379
Other assets	53,743	559,470
Accounts payable, accrued liabilities and other liabilities	3,147,091	(2,483,740)
Net cash used in operating activities	(30,530,623)	(35,991,241)
Cash flows from investing activities:
Proceeds from Sale and Maturity of Marketable Securities	7,734,528	248,000
Acquisition of property, plant and equipment	(2,573,784)	(2,925,918)
Net cash used in investing activities	(921,156)	(3,547,353)
Cash Acquired from Acquisition	0	50,894
Cash flows from financing activities:
Proceeds from exercise of options	0	271,008
Proceeds from exercise of warrants	0	1,720,725
Net proceeds from issuance of common stock	36,136,839	11,275,109
Proceeds from Issuance of Long-term Debt	0	14,476,170
Repayment of mortgage loan	0	(3,236,721)
Proceeds from notes payable	1,087,361	1,777,163
Repayment of notes payable	(903,783)	(737,333)
Net cash provided by financing activities	36,320,417	25,546,121
Net increase (decrease) in cash and cash equivalents	4,868,638	(13,992,473)
Cash and cash equivalents at beginning of period	19,174,061	46,133,759
Cash and cash equivalents at beginning of period	24,042,699	32,141,286
Cash paid during the period for:
Interest	1,122,479	359,300
Common stock and contingent consideration issued in merger	$ 0	$ 33,490,351

The Business

The Business	9 Months Ended
	Sep. 30, 2015
The Business [Abstract]
Nature of Operations [Text Block]	The Business Overview Caladrius Biosciences, Inc. (“we,” “us”, "our", “Caladrius” or the “Company”) is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. Caladrius is a company combining a leading cell therapy service provider with a development pipeline including a late-stage clinical program based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for immunomodulation and ischemic repair. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. Through our wholly owned subsidiary, PCT, LLC, a Caladrius Company ("PCT"), we are an industry leader in providing high-quality innovative and reliable manufacturing capabilities and engineering solutions ( e.g. , process and assay development, optimization and automation) in the development of cell-based therapies. In addition to leveraging this core expertise in the development of our own products, we partner with other industry leaders who recognize our unique ability to significantly improve their manufacturing processes and supply clinical and commercial product. PCT has worked with over 120 clients and produced over 20,000 cell therapy products since it was founded over sixteen years ago. We currently operate facilities qualified under current Good Manufacturing Practices ("cGMPs") in each of Allendale, NJ, Mountain View, CA and Irvine, CA, and are positioned to expand our capacity both in the United States and internationally, as needed. As the industry continues to mature and a growing number of cell therapy companies approach commercialization, PCT is well positioned to serve as an external manufacturing partner of choice for commercial cGMP manufacturing of cell therapies. Our most advanced clinical program is based on our tumor cell/dendritic cell technology. It is focused on the development of an innovative cancer immunotherapy treatment ( i.e. , vaccine) that is designed to target the cells responsible for tumor growth and metastasis, known as cancer- or tumor-initiating cells ("CICs"), using purified CICs from a patient’s own tumor as an antigen source to induce or enhance an anti-tumor immune response in the patient. CLBS20, our lead product candidate based on this platform technology, targets malignant melanoma. CLBS20 is being studied in patients with recurrent Stage III or Stage IV metastatic melanoma. The program has been granted Fast Track and Orphan designation by the Food and Drug Administration (the "FDA") as well as Advanced Therapeutic Medicinal Product classification by the European Medicines Agency (the "EMA"). The protocol for the Phase 3 study, known as the Intus study, is the subject of a Special Protocol Assessment ("SPA") by the FDA. Our SPA letter states that our Phase 3 clinical trial is adequately designed to provide the necessary data that, depending on outcome, could support a Biologics License Application ("BLA") seeking marketing approval of CLBS20. The Intus Study is the subject of a $17.7 million grant from the California Institute for Regenerative Medicine, announced in May 2015. We have also been awarded a contract from the National Cancer Institute of the National Institutes of Health for up to $2.3 million for further process optimization of the underlying platform technology. The study protocol calls for randomizing 250 patients, and patient screening began in the first quarter of 2015 with randomization of the first patient announced in April 2015. An interim analysis is planned after 99 trial events ( i.e. , deaths) and is expected to occur around the end of 2017. The treatment paradigm for metastatic melanoma continues to evolve with the recent approval of several immuno therapies, and combination therapy is already an industry focus. We believe that CLBS20 has a place in the ultimate treatment paradigm, and we will remain flexible in our clinical efforts to maximize the role of CLBS20 in this evolving landscape. We are also evaluating other clinical indications for which we may advance this program, including liver cancer, for which we have completed a successful Phase 1 trial in China, as well as ovarian, colon, kidney, brain and lung cancers. Another of our pipeline programs is based on the use of Regulatory T Cells ("Tregs") to treat diseases caused by imbalances in an individual's immune system. This novel approach seeks to restore immune balance by enhancing Treg cell number and function. Tregs are a natural part of the human immune system and regulate the activity of T effector cells, the cells that are responsible for protecting the body from viruses and other foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by T effector cells. In autoimmune disease, it is thought that deficient Treg activity permits the T effector cells to attack the body's own beneficial cells. We have entered into a strategic collaboration with Sanford Research with the goal of developing this therapy for the treatment of type 1 diabetes mellitus (“T1D”). Sanford Research is a non-profit research organization that is part of Sanford Health and supports an emerging translational research center focused on finding a cure for T1D. The initial focus of the collaboration will be the execution of a prospective, randomized, placebo-controlled, double-blind clinical trial (The Sanford Project: Trex Study) to evaluate the safety and efficacy of the Company’s Tregs product candidate, CLBS03, in adolescents with recent onset T1D. The Phase 2 study has an open and active investigational new drug application ("IND") in place and subject enrollment is expected to commence as early as the first quarter of 2016. An interim safety analysis of the data will occur after the treatment of the first 18 patients is completed, and an interim efficacy analysis is expected after the first 52 patients reach the 6 month follow-up milestone. The third of our program platforms is designed to utilize CD34 cells to regenerate tissue damaged by ischemic conditions. Ischemia occurs when the supply of oxygenated blood in the body is restricted, causing local tissue distress and death. Ischemia can lead to conditions such as chronic heart failure ("CHF") and critical limb ischemia ("CLI"). We seek to improve oxygen delivery to affected tissues through the development and formation of new blood vessels initiated or enhanced by CD34 cells. We believe that the positive suggestion of safety and therapeutic activity seen to date in the PreSERVE-AMI Phase 2 study of CLBS10 for ST segment elevation myocardial infarction ("STEMI") supports the underlying platform technology and enables the Company’s exploration of what we believe to be more commercially viable indications of chronic heart failure (CLBS14) and/or critical limb ischemia (CLBS12) as targets for further development. In the case of CLI, we are actively exploring a program to develop CLBS12 under Japan's regenerative medicine law in collaboration with Japanese development and/or manufacturing partners. Japan’s regenerative medicine law enables an expedited path to conditional approval for regenerative medicine products that show sufficient safety evidence and signals of efficacy in a Phase 2 study. This program is supported by three previous studies of autologous CD34 cells in no-option CLI patients. These other indications are early stage opportunities and require external funding and/or partnerships to proceed to the next step in clinical development. We look forward to further advancement of our cell-based therapies to the market and to helping patients suffering from life-threatening medical conditions. Coupling our development expertise with our strong process development and manufacturing capability, we believe the stage is set for us to realize meaningful clinical development of our own proprietary platform technologies and manufacturing advancements, further positioning Caladrius as a leader in the immuno-oncology field and the cell therapy industry. We anticipate requiring additional capital in order to fund the development of cell therapy product candidates and to grow the PCT business. To meet our short and long term liquidity needs, we currently expect to use existing cash and cash equivalents balances, our revenue generating activities, and a variety of other means, including our common stock purchase agreements with Aspire Capital. Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, option exercises, partnerships and/or collaborations, and/or sale of assets. In addition, we will continue to seek as appropriate grants for scientific and clinical studies from various governmental agencies and foundations. We believe that our current cash, cash equivalents and marketable securities balances and revenue generating activities, along with access to funds under our agreement with Aspire Capital, will be sufficient to fund the business through the next 12 months. While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all. If we are unable to access capital necessary to meet our long-term liquidity needs, we may have to delay or discontinue the acquisition and development of cell therapies, and/or the expansion of our business or raise funds on terms that we currently consider unfavorable. Basis of Presentation The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of September 30, 2015 and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2014 , 2013 and 2012 included in our 2014 Form 10-K. Operating results for the nine months ended September 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining the fair values of goodwill for potential goodwill impairments for our reporting units, fair values of In-Process R&D assets, fair values of acquisition-related contingent considerations, useful lives of our tangible and intangible assets, allowances for doubtful accounts, and stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions. An accounting policy is considered to be critical if it is important to the Company’s financial condition and results of operations and if it requires management’s most difficult, subjective and complex judgments in its application. Principles of Consolidation The Consolidated Financial Statements include the accounts of Caladrius Biosciences, Inc. and its wholly-owned and partially-owned subsidiaries and affiliates as listed below. Entity Percentage of Ownership Location Caladrius Biosciences, Inc. 100% United States of America NeoStem Therapies, Inc. 100% United States of America Stem Cell Technologies, Inc. 100% United States of America Amorcyte, LLC 100% United States of America PCT, LLC, a Caladrius Company 100% United States of America NeoStem Family Storage, LLC 100% United States of America Athelos Corporation (1) 97.0% United States of America PCT Allendale, LLC 100% United States of America NeoStem Oncology, LLC 100% United States of America _________________________________________________________________ (1) As of September 30, 2015 , Becton Dickinson's ownership interest in Athelos Corporation was 3.0% .

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies [Text Block]	Summary of Significant Accounting Policies In addition to the policies below, our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our 2014 Form 10-K. There were no changes to these policies during the nine months ended September 30, 2015 . Cash and Cash Equivalents Cash and cash equivalents include short-term, highly liquid, investments with maturities of 90 days or less when purchased. Marketable Securities The Company determines the appropriate classification of our marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of our marketable securities are considered as available-for-sale and carried at estimated fair values and reported in either cash equivalents or marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. We regularly review all of our investments for other-than-temporary declines in fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in fair value of an investment is below our accounting basis and this decline is other-than-temporary, we reduce the carrying value of the security we hold and record a loss for the amount of such decline. Accounts Receivable Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk. Deferred Costs Deferred costs primarily represents costs incurred on in process projects at PCT that have not been completed. The Company reviews these projects periodically to determine that the value of each project is stated at the lower of cost or market. Share-Based Compensation The Company expenses all share-based payment awards to employees, directors, advisors and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Advisor and consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant. Goodwill and Indefinite-Lived Intangible Assets Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to in process research and development ("IPR&D") projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company reviews goodwill and indefinite-lived intangible assets at least annually, or at the time a triggering event is identified for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit or the IPR&D below its carrying value. The Company tests its goodwill and indefinite-lived intangible assets each year as of December 31. The Company reviews the carrying value of goodwill and indefinite-lived intangible assets utilizing an income approach model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit’s and IPR&D's estimated fair value. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. In accordance with its accounting policy, the Company tested goodwill for impairment as of December 31, 2014, 2013, and 2012 for its two reporting units as well as its IPR&D, and concluded there was no goodwill and IPR&D impairment. As of June 30, 2015, the Company determined that IPR&D valued at $9.4 million was fully impaired (see Note 8). The Company also tested goodwill for impairment as of June 30, 2015, since the IPR&D impairment was deemed a triggering event for goodwill impairment testing purposes, and concluded there was no goodwill impairment. Definite-Lived Intangible Assets Definite-lived intangible assets consist of customer lists, manufacturing technology, tradenames, patents and rights. These intangible assets are amortized on a straight line basis over their respective useful lives. The Company reviews definite-lived intangibles assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. No triggering events were noted in the quarter ended September 30, 2015 that would require interim impairment assessment. Recognizing and Measuring Assets Acquired and Liabilities Assumed in Business Combinations at Fair Value The Company accounts for acquired businesses using the purchase method of accounting, which requires that assets acquired and liabilities assumed be recorded at date of acquisition at their respective fair values. The consolidated financial statements and results of operations reflect an acquired business after the completion of the acquisition. The fair value of the consideration paid, including contingent consideration, is assigned to the underlying net assets of the acquired business based on their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Amounts allocated to IPR&D are included on the balance sheet. Intangible assets, including IPR&D assets upon successful completion of the project and approval of the product, are amortized on a straight-line basis to amortization expense over the expected life of the asset. Significant judgments are used in determining the estimated fair values assigned to the assets acquired and liabilities assumed and in determining estimates of useful lives of long-lived assets. Fair value determinations and useful life estimates are based on, among other factors, estimates of expected future net cash flows, estimates of appropriate discount rates used to present value expected from future net cash flow streams, the timing of approvals for IPR&D projects and the timing of related product launch dates, the assessment of each asset’s life cycle, the impact of competitive trends on each asset’s life cycle and other factors. These judgments can materially impact the estimates used to allocate acquisition date fair values to assets acquired and liabilities assumed and the resulting timing and amount charged to, or recognized in current and future operating results. For these and other reasons, actual results may vary significantly from estimated results. The Company determines the acquisition date fair value of contingent consideration obligations based on a probability-weighted income approach derived from revenue estimates, post-tax gross profit levels and a probability assessment with respect to the likelihood of achieving contingent obligations including contingent payments such as milestone obligations, royalty obligations and contract earn-out criteria, where applicable. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting. The resulting probability-weighted cash flows are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligation will be revalued to estimated fair value at that time and changes in fair value will be reflected as income or expense in our consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations. Changes in assumptions utilized in our contingent consideration fair value estimates could result in an increase or decrease in our contingent consideration obligation and a corresponding charge to operating loss or income. Revenue Recognition Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts. We recognize revenues when all of the following conditions are met: • persuasive evidence of an arrangement exists; • delivery has occurred or the services have been rendered; • the fee is fixed or determinable; and • collection is probable. The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform. Revenues associated with process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. Progress billings collected prior to contract completion are recorded as unearned revenue until such time the contract is completed, which usually requires formal client acceptance. Clinical manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when contractual terms have been met. Some client agreements include multiple elements, comprised of process development and clinical manufacturing services. The Company believes that process development and clinical manufacturing services each have stand-alone value because these services can be provided separately by other companies. The Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price. Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the three months ended September 30, 2015 and 2014 , clinical services reimbursements were $ 0.9 million and $ 1.0 million , respectively. For the nine months ended September 30, 2015 and 2014 , clinical services reimbursements were $2.3 million and $2.8 million , respectively. Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of autologous adult stem cells when the cryopreservation process is completed which is approximately 24 hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments. Research and Development Costs Research and development ("R&D") expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred. To further drive the Company’s cell therapy initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned. Recently Issued Accounting Pronouncement In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (ASU) 2014-09, " Revenue from Contracts with Customers (Topic 606). " The new revenue recognition standard provides a five-step analysis to determine when and how revenue is recognized. The standard requires that a company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December 15, 2017 and will be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements. In August 2014, FASB issued ASU No. 2014-15 Preparation of Financial Statements - Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern . Under GAAP, continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements - Liquidation Basis of Accounting . Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the provisions in this ASU should be followed to determine whether to disclose information about the relevant conditions and events. The ASU is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the adoption of this ASU and its impact on the consolidated financial statements. In April 2015, the FASB issued ASU 2015-03, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for us beginning in our first quarter of 2017. Early adoption is permitted. We do not expect this adoption to have a material impact on our financial statements.

Acquisition

Acquisition	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Mergers, Acquisitions and Dispositions Disclosures [Text Block]	Acquisition On May 8, 2014 , the Company closed (the “Closing”) its acquisition (the “CSC Acquisition”) of California Stem Cell, Inc. ("CSC"), pursuant to the terms of the Agreement and Plan of Merger, dated as of April 11, 2014 (the “Merger Agreement”), by and among the Company and its acquisition subsidiaries (collectively, "Subco"), CSC and Jason Livingston, solely in his capacity as CSC stockholder representative (together with his permitted successors, the “CSC Representative”). At Closing, Fortis Advisors LLC succeeded to the duties of the CSC Representative pursuant to the Merger Agreement. Pursuant to the Merger Agreement, on the Closing date, Subco was merged with CSC (the “Merger”), with Subco surviving the Merger as a wholly-owned subsidiary of the Company. At Closing, Subco changed its legal name to NeoStem Oncology, LLC. Aggregate Merger Consideration Pursuant to the terms of the Merger Agreement, all shares of CSC common stock (“CSC Common Stock”) and CSC preferred stock (“CSC Preferred Stock”, and collectively with the CSC Common Stock, the “CSC Capital Stock”) outstanding immediately prior to the Closing, and all outstanding unexercised options to purchase CSC Common Stock (“CSC Options”) (treated as if a net exercise had occurred), were canceled and converted into the right to receive, in the aggregate (and giving effect to the liquidation preferences accorded to the CSC Preferred Stock): (1) An aggregate of 5,329,593 shares of the Company's common stock (subject to payment of nominal cash in lieu of fractional shares) (the “Closing Merger Consideration”). (2) if payable after the Closing, certain payments in an amount of up to $90.0 million in the aggregate, payable in shares of the Company's common stock or cash, in the Company’s sole discretion, in the event of the successful completion of certain milestone events in connection with the CSC Acquisition (the “Milestone Payments”, and together with the Closing Merger Consideration, the “Merger Consideration”). The fair value of the net assets acquired in the CSC Acquisition was $19.4 million . The fair value of the consideration paid by the Company was valued at $33.5 million , resulting in the recognition of goodwill in the amount of $14.1 million . The consideration paid was comprised of equity issued and milestone payments. The fair value of the equity issued by the Company was valued at $21.6 million . The fair value of the milestone payments was valued at $11.9 million , and is contingent on the achievement of certain milestones associated with the future development of the acquired programs. Such contingent consideration has been classified as a liability and will be subject to remeasurement at the end of each reporting period. The fair value of assets acquired and liabilities assumed on May 8, 2014 is as follows (in thousands): Cash and cash equivalents $ 51 Accounts receivable trade, net 45 Prepaids and other current assets 19 Property, plant and equipment, net 1,041 Other assets 201 Goodwill 14,092 In-Process R&D 34,290 Accounts payable (333 ) Accrued liabilities (2,014 ) Deferred tax liability (13,901 ) Total $ 33,491 The total cost of the acquisition has been allocated to the assets acquired and the liabilities assumed based upon their estimated fair values at the date of the acquisition. The final allocation was completed during the measurement period which was one year from the date of acquisition. Pro Forma Financial Information The following supplemental table presents unaudited consolidated pro forma financial information as if the Closing of the CSC Acquisition had occurred on January 1, 2014 (in thousands, except per share amounts): Nine Months Ended September 30, 2014 (As Reported) (Pro forma) Revenues $ 12,662 $ 13,373 Net loss $ (43,776 ) $ (46,273 ) Net loss attributable to Caladrius Biosciences, Inc. $ (43,261 ) $ (45,758 ) Net loss per share attributable to Caladrius Biosciences, Inc. $ (1.37 ) $ (1.24 ) The unaudited supplemental pro forma financial information should not be considered indicative of the results that would have occurred if the CSC Acquisition had been consummated on January 1, 2014, nor are they indicative of future results.

Available-for-Sale-Securities (

Available-for-Sale-Securities (Notes)	9 Months Ended
	Sep. 30, 2015
Available-for-sale Securities [Abstract]
Cash, Cash Equivalents, and Marketable Securities [Text Block]	Available-for-Sale-Securities The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands): September 30, 2015 December 31, 2014 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Certificate of deposits $ — $ — $ — $ — $ 249.0 $ — $ — $ 249.0 Corporate debt securities 1,729.4 — (0.6 ) 1,728.8 — — — — Money market funds 12,408.6 — — 12,408.6 12,791.9 — — 12,791.9 Municipal debt securities 4,285.3 1.5 — 4,286.8 9,317.3 1.3 — 9,318.6 Total $ 18,423.3 $ 1.5 $ (0.6 ) $ 18,424.2 $ 22,358.2 $ 1.3 $ — $ 22,359.5 Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands): September 30, 2015 December 31, 2014 Cash and cash equivalents $ 13,074.8 $ 15,279.4 Marketable securities 5,349.4 7,080.1 Total $ 18,424.2 $ 22,359.5 The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands): September 30, 2015 Amortized Cost Estimated Fair Value Less than one year $ 18,423.3 $ 18,424.2 Greater than one year — — Total $ 18,423.3 $ 18,424.2

Deferred Costs

Deferred Costs	9 Months Ended
	Sep. 30, 2015
Inventories [Abstract]
Deferred Costs	Deferred costs, representing work in process for costs incurred on process development contracts that have not been completed, were $ 3.3 million and $ 2.6 million as of September 30, 2015 and December 31, 2014 , respectively. The Company also has deferred revenue of approximately $ 4.9 million and $ 3.9 million of advance billings received as of September 30, 2015 and December 31, 2014 , respectively, related to these contracts.

Loss Per Share

Loss Per Share	9 Months Ended
	Sep. 30, 2015
Loss Per Share [Abstract]
Loss Per Share [Text Block]	Loss Per Share For the three and nine months ended September 30, 2015 and 2014 , the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share as they are anti-dilutive. At September 30, 2015 and 2014 , the Company excluded the following potentially dilutive securities: September 30 2015 2014 Stock Options 6,611,480 4,459,923 Warrants 3,516,452 3,555,956 Restricted Shares 113,579 233,982

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2015
Fair Value Measurements [Abstract]
Fair Value Disclosures [Text Block]	Fair Value Measurements The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories: Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly. Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. The Company classifies the fair value of the warrant derivative liabilities as Level 3 inputs. These inputs require material subjectivity because value is derived through the use of a lattice model that values the derivatives based on probability weighted discounted cash flows. In May 2014, the warrants expired and the value of the warrant derivative liabilities were written off and recorded in other expenses in our consolidated statement of operations. The Company classifies the fair value of contingent consideration obligations as Level 3 inputs. The Company has recognized contingent consideration obligations related to the following: • In October 2011, in connection with the acquisition (the "Amorcyte Acquisition") of Amorcyte, LLC ("Amorcyte"), contingent consideration obligations were recognized relating to earn out payments equal to 10% of the net sales of the lead product candidate CLBS10 (in the event of and following the date of first commercial sale of CLBS10, a CD34 therapy), provided that in the event the Company sublicenses CLBS10, the applicable earn out payment will be equal to 30% of any sublicensing fees, and provided further that the Company will be entitled to recover direct out-of-pocket clinical development costs not previously paid or reimbursed and any costs, expenses, liabilities and settlement amounts arising out of claims of patent infringement or otherwise challenging Amorcyte’s right to use intellectual property, by reducing any earn out payments due by 50% until such costs have been recouped in full (the “Earn Out Payments”). As of June 30, 2015, based on a thorough analysis of the available data from the PreSERVE-AMI Phase 2 clinical study for CLBS10, an updated commercial assessment, and consultation with the Company’s scientific advisory board and the Science and Technology Committee of the Board of Directors, the Company determined that it will not pursue further development of CLBS10. As a result, the Amorcyte Acquisition contingent consideration fair value decreased to $0 as of June 30, 2015, since the contingent consideration is based solely on future revenues of CLBS10. The change in estimated fair value has been recorded in other expense (income), net in our consolidated statement of operations. • In May 2014, in connection with the CSC Acquisition, contingent consideration obligations were recognized relating to milestone payments of up to $90.0 million , based on the achievement of certain milestones associated with the future development of the acquired programs. The contingent consideration fair value increased from $12.8 million as of December 31, 2014 to $13.9 million as of September 30, 2015 . The change in estimated fair value is based on the impact of the time progression to reach those milestones as of September 30, 2015 , and has been recorded in other expenses (income), net in our consolidated statement of operations. The fair value of contingent consideration obligations is based on discounted cash flow models using a probability-weighted income approach. The measurements are based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. The Company bases the timing to complete the development and approval programs on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining FDA and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2015 , and December 31, 2014 (in thousands): September 30, 2015 December 31, 2014 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Marketable securities - available for sale $ — $ 5,349.4 $ — $ 5,349.4 $ — $ 7,080.0 $ — $ 7,080.0 $ — $ 5,349.4 $ — $ 5,349.4 $ — $ 7,080.0 $ — $ 7,080.0 Liabilities: Contingent consideration $ — $ — $ 13,880.0 $ 13,880.0 $ — $ — $ 18,260.0 $ 18,260.0 $ — $ — $ 13,880.0 $ 13,880.0 $ — $ — $ 18,260.0 $ 18,260.0 There were no transfers of financial instruments to or from Levels 1, 2 or 3 during the periods presented. For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the nine months ended September 30, 2015 by type of instrument (in thousands): Nine Months Ended September 30, 2015 Contingent Consideration Total Beginning liability balance $ 18,260.0 $ 18,260.0 Change in fair value recorded in operations (4,380.0 ) (4,380.0 ) Ending liability balance $ 13,880.0 $ 13,880.0 Some of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, accounts receivable, and accounts payable. Our long-term debt and notes payable are carried at cost and approximate fair value due to their variable or fixed interest rates, which are consistent with the interest rates in the market.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	9 Months Ended
	Sep. 30, 2015
Goodwill and Other Intangible Assets [Abstract]
Goodwill and Intangible Assets [Text Block]	Goodwill and Other Intangible Assets The Company's goodwill was $25.2 million as of September 30, 2015 and December 31, 2014 . The Company's intangible assets and related accumulated amortization as of September 30, 2015 and December 31, 2014 consisted of the following (in thousands): September 30, 2015 December 31, 2014 Useful Life Gross Accumulated Amortization Net Gross Accumulated Amortization Net Customer list 10 years $ 1,000.0 $ (470.1 ) $ 529.9 $ 1,000.0 $ (395.1 ) $ 604.9 Manufacturing technology 10 years 3,900.0 (1,833.4 ) 2,066.6 3,900.0 (1,540.9 ) 2,359.1 Tradename 10 years 800.0 (376.1 ) 423.9 800.0 (316.1 ) 483.9 In process R&D Indefinite 34,290.0 — 34,290.0 43,690.0 — 43,690.0 Patent rights 19 years 669.0 (272.9 ) 396.1 669.0 (246.5 ) 422.5 Total Intangible Assets $ 40,659.0 $ (2,952.5 ) $ 37,706.5 $ 50,059.0 $ (2,498.6 ) $ 47,560.4 The Company’s IPR&D programs were acquired in the Amorcyte Acquisition (CD34 technology) and CSC Acquisition (tumor cell/dendritic cell technology). With regards to the CD34 technology, the Company determined as of June 30, 2015, based on a thorough analysis of the available data from the PreSERVE-AMI Phase 2 clinical study, an updated commercial assessment, and consultation with the Company’s scientific advisory board and the Science and Technology Committee of the Board of Directors, that it will not pursue further development of CLBS10 for the acute myocardial infarction indication upon completion of the ongoing PreSERVE-AMI Phase 2 clinical study. However, it intends to explore other potential and more commercially viable indications of chronic heart failure and/or critical limb ischemia for its CD34 cell technology platform. These other indications are early stage opportunities, and would require external funding and/or partnerships to proceed to the next step in clinical development. As a result, and given the early stage and funding constraints of these other potential opportunities, the Company determined that IPR&D valued at $9.4 million was fully impaired as of June 30, 2015. Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Cost of revenue $ 75.8 $ 78.7 $ 229.7 $ 158.4 Research and development 30.5 27.6 89.2 54.2 Selling, general and administrative 45.0 45.0 135.0 90.0 Total $ 151.3 $ 151.3 $ 453.9 $ 302.6 Estimated intangible amortization expense for the succeeding five years is as follows (in thousands): 2015 $ 151.3 2016 605.2 2017 605.2 2018 605.2 2019 605.2 Thereafter 35,134.4 Total $ 37,706.5

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2015
Accrued Liabilities [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Accrued Liabilities Accrued liabilities as of September 30, 2015 and December 31, 2014 were as follows (in thousands): September 30, 2015 December 31, 2014 Salaries, employee benefits and related taxes $ 3,827.1 $ 2,807.2 Professional fees 523.3 495.4 California Institute for Regenerative Medicine advance funding - current 600.0 — Other 3,060.8 1,020.3 Total $ 8,011.2 $ 4,322.9

Debt

Debt	9 Months Ended
	Sep. 30, 2015
Debt [Abstract]
Debt Disclosure [Text Block]	Debt Notes Payable As of September 30, 2015 and December 31, 2014 , the Company had notes payable of approximately $1.8 million and $1.6 million , respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years. Long-Term Debt On September 26, 2014, the Company entered into a loan and security agreement (the “Loan and Security Agreement”) with Oxford Finance LLC (together with its successors and assigns, the “Lender”) pursuant to which the Lender disbursed $15.0 million (the “Loan”). After repayment of all outstanding amounts due under two loans from TD Bank, N.A. in the amount of approximately $3.1 million , and deductions for debt offering/issuance costs and interim period interest, the net proceeds from Loan were $11.7 million . The debt offering/issuance costs have been recorded as debt issuance costs in other assets in the consolidated balance sheet, and will be amortized to interest expense throughout the life of the Loan using the effective interest rate method. The proceeds from the Loan may be used to satisfy the Company’s future working capital needs, including the development of its cell therapy product candidates. The Company has been making interest-only payments on the outstanding amount of Loan on a monthly basis at a rate of 8.50% per annum. On April 29, 2015, with the Company's announcement that the first patient in the Intus Study had been randomized, the interest-only payment period on the Loan was extended from October 1, 2015 to April 1, 2016, which was in accordance with the Loan and Security Agreement. Commencing on April 1, 2016, the Company will make 30 consecutive monthly payments of principal and interest. The Loan matures on September 1, 2018. At its option, the Company may prepay all amounts owed under the Loan and Security Agreement (including all accrued and unpaid interest), subject to a prepayment fee that is determined based on the date the loan is prepaid. The Company is also required to pay Lender a final payment fee equal to 8% of the Loan. The final payment fee will be amortized to interest expense throughout the life of the Loan using the effective interest rate method. The Company paid a facility fee in the amount of $100,000 in connection with Loan. Under the Loan and Security Agreement and a related mortgage, the Company granted to Lender a security interest in all of the Company’s real property and personal property now owned or hereafter acquired, excluding intellectual property, and certain other assets and exemptions. The Company also entered into a Mortgage and Absolute Assignment of Leases and Rents (the "Mortgage"). The Company also granted Lender a security interest in the shares of the Company’s subsidiaries. The Loan and Security Agreement restricts the ability of the Company to: (a) convey, lease, sell, transfer or otherwise dispose of any part of its business or property; and (b) incur any additional indebtedness. The Loan and Security Agreement provides for standard indemnification of Lender and contains representations, warranties and certain covenants of the Company. Upon the occurrence of an event of default by the Company under the Loan and Security Agreement, Lender will have customary acceleration, collection and foreclosure remedies. There are no financial covenants associated to the Loan and Security Agreement. As of September 30, 2015 , the Company was in compliance with all covenants under the Loan and Security Agreement. Estimated future principal payments, interest, and fees due under the Loan and Security Agreement are as follows: Years Ending December 31, (in millions) 2015 $ 0.3 2016 5.3 2017 6.7 2018 6.2 Total $ 18.5 During the nine months ended September 30, 2015 , the Company recognized $1.0 million of interest expense related to the Loan and Security Agreement.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2015
Shareholders’ Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Shareholders' Equity Equity Issuances June 2015 Public Offering In June 2015, the Company completed an underwritten offering of 12.5 million shares of the Company's common stock, at a public offering price of $2.00 per share. The underwriters also exercised their entire over-allotment option of 1.875 million shares. The Company received gross proceeds of $28.8 million , before deducting underwriting discounts and commissions and offering expenses payable by the Company. Aspire Purchase Agreements In November 2015, the Company entered into a common stock purchase agreement (the "Purchase Agreement") with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $30 million of shares (limited to a maximum of approximately 11.0 million shares, unless stockholder approval is obtained or certain minimum sale price levels are reached) of the Company's common stock over a 24 -month term. As consideration for entering into the Purchase Agreement, the Company issued 842,696 shares of its common stock to Aspire Capital (see Note 16). Under the Purchase Agreement, at the Company’s discretion, it may present Aspire Capital with purchase notices from time to time to purchase the Company’s common stock, provided certain price and other requirements are met. The purchase price for the shares of common stock is based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice the Company submits to Aspire Capital, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the Purchase Agreements. We have filed a registration statement with the SEC and a related prospectus supplement that covers the offering of shares of our common stock subject to the Purchase Agreement, and therefore can initiate sales to Aspire at any time. We are party to two existing agreements with Aspire Capital (the "May 2015 Purchase Agreement" and the "March 2014 Purchase Agreement", or collectively, the "Previous Purchase Agreements"). The registration statement we previously filed with the SEC to cover offerings of shares of our common stock subject to the previous Purchase Agreements has expired, and we have not, and currently have no intention to include such shares in a registration statement filed with the SEC. Unless and until we include such shares in a registration statement filed with the SEC, we are unable to initiate sales to Aspire under the Previous Purchase Agreements. Under the May 2015 Purchase Agreement, Aspire Capital is committed to purchase up to an aggregate of $30 million of shares. As consideration for entering into the May 2015 Purchase Agreement, the Company issued 364,837 shares of its common stock to Aspire Capital. The Company has not issued any additional shares under the May 2015 Purchase Agreement. Under the March 2014 Purchase Agreement, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of shares. As consideration for entering into the March 2014 Purchase Agreement, the Company issued 150,000 shares of its common stock to Aspire Capital. During the nine months ended September 30, 2015 , the Company issued 3.0 million shares of common stock under the March 2014 Purchase Agreement with Aspire for gross proceeds of $9.4 million . Overall, the Company issued 5.1 million shares under the March 2014 Purchase Agreement for gross proceeds of $20.3 million . Stock Options and Warrants The following table summarizes the activity for stock options and warrants for the nine months ended September 30, 2015 : Stock Options Warrants Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (In Thousands) Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (In Thousands) Outstanding at December 31, 2014 4,427,234 $ 9.19 6.93 $ 28.6 3,550,956 $ 14.12 2.12 $ 1.0 Changes during the period: Granted 3,036,688 $ 3.23 — $ — Exercised — $ — — $ — Forfeited (370,588 ) $ 5.32 — $ — Expired (481,854 ) $ 7.34 (34,504 ) $ 19.78 Outstanding at September 30, 2015 6,611,480 $ 6.82 7.36 $ 15.2 3,516,452 $ 14.06 1.39 $ — Vested at September 30, 2015 or expected to vest in the future 6,362,987 $ 6.94 7.28 $ 13.2 3,516,452 $ 14.06 1.39 $ — Vested at September 30, 2015 4,685,074 $ 7.91 6.69 $ — 3,516,452 $ 14.06 1.39 $ — Restricted Stock During the nine months ended September 30, 2015 and 2014 , the Company issued restricted stock for services as follows (in thousands, except share data): Nine Months Ended September 30, 2015 2014 Number of Restricted Stock Issued 811,835 708,706 Value of Restricted Stock Issued $ 2,367.5 $ 4,964.0 The weighted average estimated fair value of restricted stock issued for services in the nine months ended September 30, 2015 and 2014 was $ 3.10 and $ 7.00 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance.

Share-Based Compensation (Notes

Share-Based Compensation (Notes)	9 Months Ended
	Sep. 30, 2015
Share-based Compensation [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Share-Based Compensation Share-based Compensation We utilize share-based compensation in the form of stock options, warrants and restricted stock. The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2015 and 2014 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Cost of goods sold $ 14.4 $ 55.9 $ 509.5 $ 292.6 Research and development 115.9 515.7 1,642.8 1,364.2 Selling, general and administrative 306.2 2,716.3 6,416.2 7,284.7 Total share-based compensation expense $ 436.5 $ 3,287.9 $ 8,568.5 $ 8,941.5 Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at September 30, 2015 were as follows (in thousands): Stock Options Warrants Restricted Stock Unrecognized compensation cost $ 3,898.6 $ — $ 336.5 Expected weighted-average period in years of compensation cost to be recognized 3.27 2.67 Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September 30, 2015 and 2014 were as follows (in thousands): Stock Options Warrants Nine Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Total fair value of shares vested $ 5,303.9 $ 4,141.6 $ — $ 15.3 Weighted average estimated fair value of shares granted $ 2.10 $ 4.67 $ — $ — Valuation Assumptions The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.

Research Funding

Research Funding	9 Months Ended
	Sep. 30, 2015
Research and Development [Abstract]
Research Funding	Research Funding California Institute for Regenerative Medicine In June 2015, the California Institute for Regenerative Medicine ("CIRM") granted the Company a $17.7 million award (the "Award") to fund a significant portion of its Phase 3 Intus study for treating patients with recurrent Stage III or Stage IV metastatic melanoma. The Award provides for a $3.0 million project initiation payment, and $14.7 million in future operational milestone payments, and is subject to a dollar-for-dollar match funding by the Company. On June 30, 2015, the Company received the $3.0 million project initiation payment from CIRM, which will be amortized over the estimated Award period as a reduction to the related research and development expenses. Future operational milestone payments will be recorded as a reduction to research and development expenses when the milestone is achieved and payment is received or probable. The State of California has the right to receive, subject to the terms and conditions of the agreement between the Company and CIRM, future payments from the Company, or its collaborators, from sales of a commercial product resulting from research and development efforts supported by the grant, of up to nine times of the Award.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Taxes [Abstract]
Income Tax Disclosure [Text Block]	Income Taxes As of December 31, 2014 , the Company had approximately $177.2 million of Federal net operating loss carryforwards ("NOLs") available to offset future taxable income expiring from 2025 through 2033. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. If a change of ownership did occur there would be an annual limitation on the usage of the Company’s losses which are available through 2032. In assessing the ability to realize deferred tax assets, including the NOLs, the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time. Deferred tax liabilities were $14.6 million and $18.2 million as of September 30, 2015 and December 31, 2014 , respectively, and relate to the taxable temporary differences on (i) the goodwill recognized in the PCT acquisition in 2011, (ii) the in-process R&D intangible asset recognized in the Amorcyte Acquisition in 2011, and (iii) the IPR&D intangible asset recognized in the CSC Acquisition in 2014. The taxable temporary difference associated with the goodwill, which is tax deductible and will be amortized over 15 years, will continue to increase the deferred tax liability balance over the amortization period, with an associated charge to the tax provision in each period. The deferred tax liabilities will only reverse when these indefinite-lived assets are sold, impaired, or reclassified from an indefinite-lived asset to a finite-lived asset. As of June 30, 2015, IPR&D recognized in the Amorcyte Acquisition and valued at $9.4 million was fully impaired (see Note 8), resulting in the reversal of the associated deferred tax liability of $3.7 million . As of September 30, 2015 , management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year. The Company's federal tax returns are currently being audited for the years 2012 and 2013. For years prior to 2011 the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of 3 to 4 years from date of filing. The Company ceased doing business in China in 2012. After 2012, the Company had no foreign tax filing obligations. The returns filed for 2012 and prior are subject to examination for 5 years.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies [Abstract]
Commitments and Contingencies [Text Block]	Commitments and Contingencies Lease Commitments We entered into an assignment agreement with an unaffiliated third party, effective February 19, 2015, for general office space located in Basking Ridge, NJ. This property is used as the Company's corporate headquarters. The space is approximately 18,000 rentable square feet. The base monthly rent is currently $25,000 and the lease term ends July 31, 2020. In addition, there are two (2) five (5) year renewal options. In connection with the assumption of the lease, the third party (a) conveyed its rights in various scheduled furniture and equipment and (b) paid the Company approximately $580,000 . The amount paid to the Company included a security deposit of approximately $115,000 . The Company also leases facilities in New York, NY, Irvine, CA, and Mountain View, CA, of which certain have escalation clauses and renewal options, and also leases equipment under certain noncancelable operating leases that expire from time to time through 2021. A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of September 30, 2015 are as follows (in thousands): Years ended Operating Leases 2015 $ 492.8 2016 2,062.0 2017 1,863.8 2018 1,034.8 2019 and thereafter 1,949.6 Total minimum lease payments $ 7,403.0 Expense incurred under operating leases was approximately $0.4 million and $0.4 million for the three months ended September 30, 2015 and 2014 , respectively. Expense incurred under operating leases was approximately $1.2 million and $0.9 million for the nine months ended September 30, 2015 and 2014 , respectively. Contingencies We have entered into a strategic collaboration with Sanford Research with the goal of developing a therapy for the treatment of T1D. The initial focus of the collaboration will be the execution of a prospective, randomized, placebo-controlled, double-blind clinical trial (The Sanford Project: Trex Study) to evaluate the safety and efficacy of the Company’s T regulatory cell product candidate, CLBS03, in adolescents with recent onset T1D. The Phase 2 study has an open and active IND in place and subject enrollment is expected to commence as early as the first quarter of 2016. We will be initially responsible for the supply of all study drug to the first 18 enrolled patients upon commencement of the study. Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research. From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.

Subsequent Events (Notes)

Subsequent Events (Notes)	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events November 2015 Aspire Capital Agreement In November, 2015, the Company entered into a Common Stock Purchase Agreement with Aspire Capital, whereby Aspire Capital is committed to purchase up to an aggregate of $30 million of shares (limited to a maximum of approximately 11.0 million shares, unless stockholder approval is obtained or certain minimum sales price levels are met) of the Company's common stock over a 24 -month term. As consideration for entering into the Purchase Agreement, the Company issued 842,696 shares of its common stock to Aspire Capital.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Summary of Significant Accounting Policies [Abstract]
Schedule of Cash and Cash Equivalents [Table Text Block]	Cash and Cash Equivalents Cash and cash equivalents include short-term, highly liquid, investments with maturities of 90 days or less when purchased.
Marketable Securities, Policy [Policy Text Block]	Marketable Securities The Company determines the appropriate classification of our marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of our marketable securities are considered as available-for-sale and carried at estimated fair values and reported in either cash equivalents or marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. We regularly review all of our investments for other-than-temporary declines in fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in fair value of an investment is below our accounting basis and this decline is other-than-temporary, we reduce the carrying value of the security we hold and record a loss for the amount of such decline.
Receivables, Policy [Policy Text Block]	Accounts Receivable Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk.
Inventory Disclosure [Text Block]	Deferred costs primarily represents costs incurred on in process projects at PCT that have not been completed. The Company reviews these projects periodically to determine that the value of each project is stated at the lower of cost or market.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill and Indefinite-Lived Intangible Assets
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts. We recognize revenues when all of the following conditions are met: • persuasive evidence of an arrangement exists; • delivery has occurred or the services have been rendered; • the fee is fixed or determinable; and • collection is probable. The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform. Revenues associated with process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. Progress billings collected prior to contract completion are recorded as unearned revenue until such time the contract is completed, which usually requires formal client acceptance. Clinical manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when contractual terms have been met. Some client agreements include multiple elements, comprised of process development and clinical manufacturing services. The Company believes that process development and clinical manufacturing services each have stand-alone value because these services can be provided separately by other companies. The Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price. Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the three months ended September 30, 2015 and 2014 , clinical services reimbursements were $ 0.9 million and $ 1.0 million , respectively. For the nine months ended September 30, 2015 and 2014 , clinical services reimbursements were $2.3 million and $2.8 million , respectively. Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of autologous adult stem cells when the cryopreservation process is completed which is approximately 24 hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncement In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (ASU) 2014-09, " Revenue from Contracts with Customers (Topic 606). " The new revenue recognition standard provides a five-step analysis to determine when and how revenue is recognized. The standard requires that a company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December 15, 2017 and will be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements. In August 2014, FASB issued ASU No. 2014-15 Preparation of Financial Statements - Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern . Under GAAP, continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements - Liquidation Basis of Accounting . Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the provisions in this ASU should be followed to determine whether to disclose information about the relevant conditions and events. The ASU is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the adoption of this ASU and its impact on the consolidated financial statements. In April 2015, the FASB issued ASU 2015-03, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for us beginning in our first quarter of 2017. Early adoption is permitted. We do not expect this adoption to have a material impact on our financial statements.

The Business (Tables)

The Business (Tables)	9 Months Ended
	Sep. 30, 2015
The Business [Abstract]
Subsidiary [Table Text Block]	Entity Percentage of Ownership Location Caladrius Biosciences, Inc. 100% United States of America NeoStem Therapies, Inc. 100% United States of America Stem Cell Technologies, Inc. 100% United States of America Amorcyte, LLC 100% United States of America PCT, LLC, a Caladrius Company 100% United States of America NeoStem Family Storage, LLC 100% United States of America Athelos Corporation (1) 97.0% United States of America PCT Allendale, LLC 100% United States of America NeoStem Oncology, LLC 100% United States of America

Acquisition (Tables)

Acquisition (Tables)	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Business Acquisition, Pro Forma Information [Table Text Block]	The following supplemental table presents unaudited consolidated pro forma financial information as if the Closing of the CSC Acquisition had occurred on January 1, 2014 (in thousands, except per share amounts): Nine Months Ended September 30, 2014 (As Reported) (Pro forma) Revenues $ 12,662 $ 13,373 Net loss $ (43,776 ) $ (46,273 ) Net loss attributable to Caladrius Biosciences, Inc. $ (43,261 ) $ (45,758 ) Net loss per share attributable to Caladrius Biosciences, Inc. $ (1.37 ) $ (1.24 )
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The fair value of assets acquired and liabilities assumed on May 8, 2014 is as follows (in thousands): Cash and cash equivalents $ 51 Accounts receivable trade, net 45 Prepaids and other current assets 19 Property, plant and equipment, net 1,041 Other assets 201 Goodwill 14,092 In-Process R&D 34,290 Accounts payable (333 ) Accrued liabilities (2,014 ) Deferred tax liability (13,901 ) Total $ 33,491

Available-for-Sale-Securities27

Available-for-Sale-Securities (Tables)	9 Months Ended
	Sep. 30, 2015
Available-for-sale Securities [Abstract]
Schedule of Available-for-sale Securities Reconciliation [Table Text Block]	The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands): September 30, 2015 December 31, 2014 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Estimated Fair Value Certificate of deposits $ — $ — $ — $ — $ 249.0 $ — $ — $ 249.0 Corporate debt securities 1,729.4 — (0.6 ) 1,728.8 — — — — Money market funds 12,408.6 — — 12,408.6 12,791.9 — — 12,791.9 Municipal debt securities 4,285.3 1.5 — 4,286.8 9,317.3 1.3 — 9,318.6 Total $ 18,423.3 $ 1.5 $ (0.6 ) $ 18,424.2 $ 22,358.2 $ 1.3 $ — $ 22,359.5
Marketable Securities [Table Text Block]	Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands): September 30, 2015 December 31, 2014 Cash and cash equivalents $ 13,074.8 $ 15,279.4 Marketable securities 5,349.4 7,080.1 Total $ 18,424.2 $ 22,359.5
Investments Classified by Contractual Maturity Date [Table Text Block]	The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands): September 30, 2015 Amortized Cost Estimated Fair Value Less than one year $ 18,423.3 $ 18,424.2 Greater than one year — — Total $ 18,423.3 $ 18,424.2

Loss Per Share (Tables)

Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2015
Loss Per Share [Abstract]
ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block]	At September 30, 2015 and 2014 , the Company excluded the following potentially dilutive securities: September 30 2015 2014 Stock Options 6,611,480 4,459,923 Warrants 3,516,452 3,555,956 Restricted Shares 113,579 233,982

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Measurements [Abstract]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis, Valuation Techniques [Table Text Block]	• In October 2011, in connection with the acquisition (the "Amorcyte Acquisition") of Amorcyte, LLC ("Amorcyte"), contingent consideration obligations were recognized relating to earn out payments equal to 10% of the net sales of the lead product candidate CLBS10 (in the event of and following the date of first commercial sale of CLBS10, a CD34 therapy), provided that in the event the Company sublicenses CLBS10, the applicable earn out payment will be equal to 30% of any sublicensing fees, and provided further that the Company will be entitled to recover direct out-of-pocket clinical development costs not previously paid or reimbursed and any costs, expenses, liabilities and settlement amounts arising out of claims of patent infringement or otherwise challenging Amorcyte’s right to use intellectual property, by reducing any earn out payments due by 50% until such costs have been recouped in full (the “Earn Out Payments”). As of June 30, 2015, based on a thorough analysis of the available data from the PreSERVE-AMI Phase 2 clinical study for CLBS10, an updated commercial assessment, and consultation with the Company’s scientific advisory board and the Science and Technology Committee of the Board of Directors, the Company determined that it will not pursue further development of CLBS10. As a result, the Amorcyte Acquisition contingent consideration fair value decreased to $0 as of June 30, 2015, since the contingent consideration is based solely on future revenues of CLBS10. The change in estimated fair value has been recorded in other expense (income), net in our consolidated statement of operations. • In May 2014, in connection with the CSC Acquisition, contingent consideration obligations were recognized relating to milestone payments of up to $90.0 million , based on the achievement of certain milestones associated with the future development of the acquired programs. The contingent consideration fair value increased from $12.8 million as of December 31, 2014 to $13.9 million as of September 30, 2015 . The change in estimated fair value is based on the impact of the time progression to reach those milestones as of September 30, 2015 , and has been recorded in other expenses (income), net in our consolidated statement of operations. The fair value of contingent consideration obligations is based on discounted cash flow models using a probability-weighted income approach. The measurements are based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. The Company bases the timing to complete the development and approval programs on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining FDA and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2015 , and December 31, 2014 (in thousands): September 30, 2015 December 31, 2014 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets: Marketable securities - available for sale $ — $ 5,349.4 $ — $ 5,349.4 $ — $ 7,080.0 $ — $ 7,080.0 $ — $ 5,349.4 $ — $ 5,349.4 $ — $ 7,080.0 $ — $ 7,080.0 Liabilities: Contingent consideration $ — $ — $ 13,880.0 $ 13,880.0 $ — $ — $ 18,260.0 $ 18,260.0 $ — $ — $ 13,880.0 $ 13,880.0 $ — $ — $ 18,260.0 $ 18,260.0
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the nine months ended September 30, 2015 by type of instrument (in thousands): Nine Months Ended September 30, 2015 Contingent Consideration Total Beginning liability balance $ 18,260.0 $ 18,260.0 Change in fair value recorded in operations (4,380.0 ) (4,380.0 ) Ending liability balance $ 13,880.0 $ 13,880.0

Goodwill and Other Intangible30

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill and Other Intangible Assets [Abstract]
Schedule of Goodwill [Table Text Block]	The Company's goodwill was $25.2 million as of September 30, 2015 and December 31, 2014 .
Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block]	The Company's intangible assets and related accumulated amortization as of September 30, 2015 and December 31, 2014 consisted of the following (in thousands): September 30, 2015 December 31, 2014 Useful Life Gross Accumulated Amortization Net Gross Accumulated Amortization Net Customer list 10 years $ 1,000.0 $ (470.1 ) $ 529.9 $ 1,000.0 $ (395.1 ) $ 604.9 Manufacturing technology 10 years 3,900.0 (1,833.4 ) 2,066.6 3,900.0 (1,540.9 ) 2,359.1 Tradename 10 years 800.0 (376.1 ) 423.9 800.0 (316.1 ) 483.9 In process R&D Indefinite 34,290.0 — 34,290.0 43,690.0 — 43,690.0 Patent rights 19 years 669.0 (272.9 ) 396.1 669.0 (246.5 ) 422.5 Total Intangible Assets $ 40,659.0 $ (2,952.5 ) $ 37,706.5 $ 50,059.0 $ (2,498.6 ) $ 47,560.4
Schedule of Amortization Expense [Table Text Block]	Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Cost of revenue $ 75.8 $ 78.7 $ 229.7 $ 158.4 Research and development 30.5 27.6 89.2 54.2 Selling, general and administrative 45.0 45.0 135.0 90.0 Total $ 151.3 $ 151.3 $ 453.9 $ 302.6
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated intangible amortization expense for the succeeding five years is as follows (in thousands): 2015 $ 151.3 2016 605.2 2017 605.2 2018 605.2 2019 605.2 Thereafter 35,134.4 Total $ 37,706.5

Accrued Liabilities Accrued Lia

Accrued Liabilities Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2015
Accrued Liabilities [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued liabilities as of September 30, 2015 and December 31, 2014 were as follows (in thousands): September 30, 2015 December 31, 2014 Salaries, employee benefits and related taxes $ 3,827.1 $ 2,807.2 Professional fees 523.3 495.4 California Institute for Regenerative Medicine advance funding - current 600.0 — Other 3,060.8 1,020.3 Total $ 8,011.2 $ 4,322.9

Debt Long term debt (Tables)

Debt Long term debt (Tables)	9 Months Ended
	Sep. 30, 2015
Long-term Debt, Unclassified [Abstract]
Schedule of Maturities of Long-term Debt [Table Text Block]	Estimated future principal payments, interest, and fees due under the Loan and Security Agreement are as follows: Years Ending December 31, (in millions) 2015 $ 0.3 2016 5.3 2017 6.7 2018 6.2 Total $ 18.5

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2015
Shareholders’ Equity [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes the activity for stock options and warrants for the nine months ended September 30, 2015 : Stock Options Warrants Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (In Thousands) Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value (In Thousands) Outstanding at December 31, 2014 4,427,234 $ 9.19 6.93 $ 28.6 3,550,956 $ 14.12 2.12 $ 1.0 Changes during the period: Granted 3,036,688 $ 3.23 — $ — Exercised — $ — — $ — Forfeited (370,588 ) $ 5.32 — $ — Expired (481,854 ) $ 7.34 (34,504 ) $ 19.78 Outstanding at September 30, 2015 6,611,480 $ 6.82 7.36 $ 15.2 3,516,452 $ 14.06 1.39 $ — Vested at September 30, 2015 or expected to vest in the future 6,362,987 $ 6.94 7.28 $ 13.2 3,516,452 $ 14.06 1.39 $ — Vested at September 30, 2015 4,685,074 $ 7.91 6.69 $ — 3,516,452 $ 14.06 1.39 $ —
Restricted Stock [Table Text Block]	During the nine months ended September 30, 2015 and 2014 , the Company issued restricted stock for services as follows (in thousands, except share data): Nine Months Ended September 30, 2015 2014 Number of Restricted Stock Issued 811,835 708,706 Value of Restricted Stock Issued $ 2,367.5 $ 4,964.0

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2015
Share-based Compensation [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2015 and 2014 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Cost of goods sold $ 14.4 $ 55.9 $ 509.5 $ 292.6 Research and development 115.9 515.7 1,642.8 1,364.2 Selling, general and administrative 306.2 2,716.3 6,416.2 7,284.7 Total share-based compensation expense $ 436.5 $ 3,287.9 $ 8,568.5 $ 8,941.5
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at September 30, 2015 were as follows (in thousands): Stock Options Warrants Restricted Stock Unrecognized compensation cost $ 3,898.6 $ — $ 336.5 Expected weighted-average period in years of compensation cost to be recognized 3.27 2.67
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]	Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September 30, 2015 and 2014 were as follows (in thousands): Stock Options Warrants Nine Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Total fair value of shares vested $ 5,303.9 $ 4,141.6 $ — $ 15.3 Weighted average estimated fair value of shares granted $ 2.10 $ 4.67 $ — $ — Valuation Assumptions The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of September 30, 2015 are as follows (in thousands): Years ended Operating Leases 2015 $ 492.8 2016 2,062.0 2017 1,863.8 2018 1,034.8 2019 and thereafter 1,949.6 Total minimum lease payments $ 7,403.0

The Business (Details)

The Business (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
The Company [Line Items]
Subsidiary, Ownership Interest by Parent	97.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	3.00%
Change in Ownership in Subsidiary	$ 0	$ 0
Noncontrolling Interest [Member]
The Company [Line Items]
Change in Ownership in Subsidiary	$ 101,367	$ 86,617
NeoStem, Inc. [Member]
The Company [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%

The Business Principal of conso

The Business Principal of consolidation (Details)	Sep. 30, 2015
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	97.00%
NeoStem, Inc. [Member]
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Therapies, Inc [Member] | UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Stem Cell Technologies, Inc [Member] | UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Amorcyte, LLC [Member] | UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Progenitor Cell Therapy, LLC [Member] | UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Family Storage, LLC [Member] | UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
PCT Allendale, LLC [Member] | UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Oncology [Member] | UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%

Summary of Significant Accoun38

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Summary of Significant Accounting Policies [Abstract]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 0	$ 0	$ 9,400,000	$ 0
Clinical Services Reimbursement	$ 900,000	$ 1,000,000	$ 2,300,000	$ 2,800,000

Acquisition (Details)

Acquisition (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	May. 08, 2014
Business Acquisition [Line Items]
Change in acquisition-related contingent consideration			$ (4,380,000)	$ 1,090,000
Revenues	$ 5,888,450	$ 4,117,783	14,927,691	12,662,290
Net loss	$ (11,392,857)	$ (17,176,644)	$ (47,782,363)	(43,776,220)
Common Stock, Shares, Issued	55,497,240		55,497,240		36,783,857	5,329,593
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High						$ 90,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net						19,400,000
Acquisition-related contingent consideration	$ 13,880,000		$ 13,880,000		$ 18,260,000	11,900,000
Business Acquisition, Transaction Costs						33,500,000
Cash and cash equivalents						51,000
Accounts receivable, net of allowance for doubtful accounts of $390,118 and $391,829 at March 31, 2014 and December 31, 2013, respectively						45,000
Prepaid expenses and other current assets						19,000
Property, plant and equipment, net						1,041,000
Other assets						201,000
Goodwill	$ 25,209,336		25,209,336		$ 25,209,336	14,092,000
Equity Issued in Business Combination, Fair Value Disclosure						21,600,000
Intangible assets, net						34,290,000
Accounts Payable, Current						(333,000)
Accrued Liabilities, Current						(2,014,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent						(13,901,000)
Deferred Tax Liabilities, Net, Noncurrent			$ 3,610,097	$ (142,183)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$ (0.21)	$ (0.48)	$ (1.04)	$ (1.37)
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net						$ 33,491,000
NeoStem Oncology [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue				$ 13,373,000
Business Acquisition, Pro Forma Net Income (Loss)				(46,273,000)
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual				$ (45,758,000)
Business Acquisition, Pro Forma Earnings Per Share, Diluted				$ (1.24)
NeoStem, Inc. [Member]
Business Acquisition [Line Items]
Revenues				$ 12,662,000
Net loss				(43,776,000)
Net Income (Loss) Attributable to Parent				$ (43,261,000)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders				$ (1.37)

Available-for-Sale-Securities S

Available-for-Sale-Securities Schedule of Available-for-sale Securites Reconciliation (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	$ 18,423,300	$ 22,358,200
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	1,500	1,300
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	(600)	0
Certificates of Deposit, at Carrying Value	18,424,200	22,359,500
Certificates of Deposit [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	0	249,000
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0	0
Certificates of Deposit, at Carrying Value	0	249,000
Corporate Debt Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	1,729,400	0
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	(600)	0
Certificates of Deposit, at Carrying Value	1,728,800	0
Money Market Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	12,408,600	12,791,900
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	0	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0	0
Certificates of Deposit, at Carrying Value	12,408,600	12,791,900
Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	4,285,300	9,317,300
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	1,500	1,300
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0	0
Certificates of Deposit, at Carrying Value	$ 4,286,800	$ 9,318,600

Available-for-Sale-Securities C

Available-for-Sale-Securities Classification of the available-for-sale securities (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Available-for-sale Securities [Abstract]
Cash	$ 13,074,800	$ 15,279,400
Marketable securities	5,349,400	7,080,100
Total	$ 18,424,200	$ 22,359,500

Available-for-Sale-Securities A

Available-for-Sale-Securities Available-for-sale Securities by Contractual Maturity (Details)	Sep. 30, 2015USD ($)
Available-for-sale Securities [Abstract]
Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis	$ 0
Available-for-sale Securities, Debt Maturities, Remainder of Fiscal Year, Amortized Cost Basis	18,424,200
Available-for-sale Securities, Noncurrent	0
Amortized Cost	18,423,300
Estimated Fair Value	$ 18,424,200

Deferred Costs (Details)

Deferred Costs (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Schedule of Inventory [Line Items]
Deferred costs	$ 3,348,619	$ 2,566,989
Multiple Stage Contracts [Member]
Schedule of Inventory [Line Items]
Deferred Revenue	$ 4,900,000	$ 3,900,000

Loss Per Share (Details)

Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Warrants
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	3,516,452	3,555,956
Stock Options [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	6,611,480	4,459,923
Restricted Stock [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	113,579	233,982

Fair Value Measurements Fair va

Fair Value Measurements Fair value hierarchy the Company’s financial assets and liabilities (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	May. 08, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration	$ 13,880,000	$ 18,260,000	$ 11,900,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			$ 90,000,000
Accrued Liabilities and Other Liabilities	13,880,000	18,260,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized	13,900,000	12,800,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Classified as Equity, Fair Value Disclosure	0	0
Accrued Liabilities and Other Liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Classified as Equity, Fair Value Disclosure	0	0
Accrued Liabilities and Other Liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Classified as Equity, Fair Value Disclosure	13,880,000	18,260,000
Accrued Liabilities and Other Liabilities	13,880,000	18,260,000
Contingent Consideration Classified as Equity [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration	13,880,000	18,260,000
Amorcyte, LLC [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration	0
Contingent Consideration Classified as Equity [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Classified as Equity, Fair Value Disclosure	$ 13,880,000	$ 18,260,000

Fair Value Measurements Financi

Fair Value Measurements Financial instruments with significant Level 3 inputs (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	May. 08, 2014	Oct. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	$ 5,349,400		$ 7,080,000
Percentage of Net Sales					10.00%
Percentage of license cost					30.00%
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition-related contingent consideration	13,880,000		18,260,000	$ 11,900,000
Accrued Liabilities and Other Liabilities	13,880,000		18,260,000
Change in acquisition-related contingent consideration	(4,380,000)	$ 1,090,000
Fair Value, Option, Changes in Fair Value, Gain (Loss)	(4,380,000)
Contingent Consideration Classified as Equity [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition-related contingent consideration	13,880,000		18,260,000
Change in acquisition-related contingent consideration	(4,380,000)
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0		0
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Accrued Liabilities and Other Liabilities	0		0
Contingent Consideration Classified as Equity, Fair Value Disclosure	0		0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	5,349,400		7,080,000
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Accrued Liabilities and Other Liabilities	0		0
Contingent Consideration Classified as Equity, Fair Value Disclosure	0		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0		0
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Accrued Liabilities and Other Liabilities	13,880,000		18,260,000
Contingent Consideration Classified as Equity, Fair Value Disclosure	13,880,000		$ 18,260,000
Amorcyte, LLC [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition-related contingent consideration	$ 0

Goodwill and Other Intangible47

Goodwill and Other Intangible Assets Intangible Assets and Related Accumulated Amortization (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 0	$ 0	$ 9,400,000	$ 0
Goodwill [Roll Forward]
Goodwill	25,209,336		25,209,336
Finite-Lived Intangible Assets, Gross	40,659,000		40,659,000		$ 50,059,000
Finite-Lived Intangible Assets, Accumulated Amortization	(2,952,500)		(2,952,500)		(2,498,600)
Finite-Lived Intangible Assets, Future Amortization Expense	37,706,500		37,706,500		47,560,400
Customer Lists [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	1,000,000		1,000,000		1,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	(470,100)		(470,100)		(395,100)
Finite-Lived Intangible Assets, Future Amortization Expense	529,900		$ 529,900		604,900
Finite-Lived Intangible Assets, Useful Life			10 years
Manufacturing Technology [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	3,900,000		$ 3,900,000		3,900,000
Finite-Lived Intangible Assets, Accumulated Amortization	(1,833,400)		(1,833,400)		(1,540,900)
Finite-Lived Intangible Assets, Future Amortization Expense	2,066,600		$ 2,066,600		2,359,100
Finite-Lived Intangible Assets, Useful Life			10 years
Trade Names [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	800,000		$ 800,000		800,000
Finite-Lived Intangible Assets, Accumulated Amortization	(376,100)		(376,100)		(316,100)
Finite-Lived Intangible Assets, Future Amortization Expense	423,900		$ 423,900		483,900
Finite-Lived Intangible Assets, Useful Life			10 years
In Process R and D [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	34,290,000		$ 34,290,000		43,690,000
Finite-Lived Intangible Assets, Accumulated Amortization	0		0		0
Finite-Lived Intangible Assets, Future Amortization Expense	34,290,000		34,290,000		43,690,000
VSEL Patent Rights [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	669,000		669,000		669,000
Finite-Lived Intangible Assets, Accumulated Amortization	(272,900)		(272,900)		(246,500)
Finite-Lived Intangible Assets, Future Amortization Expense	$ 396,100		$ 396,100		$ 422,500
Finite-Lived Intangible Assets, Useful Life			19 years

Goodwill and Other Intangible48

Goodwill and Other Intangible Assets Intangible Amortization Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 151,300	$ 151,300	$ 453,900	$ 302,600
Cost of revenue
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	75,800	78,700	229,700	158,400
Research and development
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	30,500	27,600	89,200	54,200
Selling, general and administrative
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 45,000	$ 45,000	$ 135,000	$ 90,000

Goodwill and Other Intangible49

Goodwill and Other Intangible Assets Goodwill (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Goodwill [Abstract]
Goodwill	$ 25,200,000
Future Amortization Expense, Year One	151,300
Future Amortization Expense, Year Two	605,200
Future Amortization Expense, Year Three	605,200
Future Amortization Expense, Year Four	605,200
Future, Amortization Expense, Year Five	605,200
Thereafter	35,134,400
Finite-Lived Intangible Assets, Future Amortization Expense	$ 37,706,500	$ 47,560,400

Accrued Liabilities Accrued L50

Accrued Liabilities Accrued Liabilities (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Accrued Liabilities [Abstract]
Salaries, employee benefits and related taxes	$ 3,827,100	$ 2,807,200
Professional fees	523,300	495,400
Other	3,060,800	1,020,300
Accrued Liabilities	8,011,200	4,322,900
Funds Held for Clients	$ 600,000	$ 0

Debt (Details)

Debt (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Sep. 26, 2014
Debt Instrument [Line Items]
Notes Payable	$ 1,800,000	$ 1,600,000
Proceeds from Issuance of Debt	11,700,000
Debt Issuance Cost	(100,000)
Mortgage Loans on Real Estate, Carrying Amount of Mortgages	3,100,000
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Two	300,000
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Three	5,300,000
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Four	6,700,000
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Five	6,200,000
Long-term Debt	18,500,000
Interest expense	$ 1,000,000
Impaired Long-Lived Assets Held and Used, Asset Name [Domain]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Interest	8.00%
Long-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum	8.50%
Aspire Capital Purchase Agreement [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross			$ 15,000,000
NeoStem, Inc. [Member] | Long-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Payment Terms	30 months

Shareholders' Equity Equity Iss

Shareholders' Equity Equity Issuances (Details) - USD ($)	1 Months Ended	9 Months Ended
	Nov. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	May. 01, 2015	Dec. 31, 2014	Jun. 30, 2014	May. 08, 2014
Class of Stock [Line Items]
Common Stock, Shares, Issued		55,497,240			36,783,857		5,329,593
Net proceeds from issuance of common stock		$ 36,136,839	$ 11,275,109
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Other		12,500,000
Fair Value Inputs, Offered Quotes		$ 2
Net proceeds from issuance of common stock		$ 28,800,000
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues		3,000,000
Net proceeds from issuance of common stock		$ 9,400,000
Over-Allotment Option [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Other		1,875,000
March 2014 Purchase Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Other		5,100,000
Net proceeds from issuance of common stock		$ 20,300,000
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Common Stock, Shares, Issued		364,837				150,000
Purchase Commitment, Remaining Minimum Amount Committed				$ 30,000,000		$ 30,000,000
Subsequent Event [Member] | Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Term of agreement in months	24 months
Purchase Commitment, Remaining Minimum Amount Committed	$ 30,000,000
Purchase Commitment, Maximum Amount Committed, Shares	11,019,276
Stock Issued During Period, Shares, Other	842,696
Discount Applied To Weighted Average Price	5.00%

Shareholders' Equity Stock opti

Shareholders' Equity Stock options and warrants (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2015USD ($)$ / shares$ / warrantshares	Dec. 31, 2014USD ($)$ / shares$ / warrantshares
Stock Options and Warrants [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | $	$ 15,200	$ 28,600
Common Stock Warrants, Shares	3,516,452	3,550,956
Weighted Average Exercise Price, Warrants Outstanding | $ / warrant	14.06	14.12
Weighted Average Remaining Contractual Term warrant outstanding	1 year 4 months 21 days	2 years 1 month 13 days
Aggregate Intrinsic Value, Warrants Outstanding | $	$ 0	$ 1,000
Warrants Granted	0
Warrants Canceled	34,504
Weighted Average Exercise Price, Warrants Granted | $ / shares	$ 0
Warrants Exercised	0
Weighted Average Exercise Price, Warrants Exercised | $ / shares	$ 0
Warrants Expired	0
Weighted Average Exercise Price, Warrants Expired | $ / shares	$ 0
Weighted Average Exercise Price, Warrants Canceled | $ / shares	$ 19.78
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | $	$ 13,200
shares, vested and expected to vest	3,516,452
Weighted Average Exercise Price, Warrants vested & expected to vest | $ / warrant	14.06
Aggregate Intrinsic Value, Warrants vested and expected to vest | $	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | $	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	3,516,452
Weighted Average Exercise Price, Warrants Exercisable | $ / warrant	14.06
weighted Average Remaining Contractual Term, warrants vested	1 year 4 months 21 days
Aggregate Intrinsic Value, Warrants vested | $	$ 0
US Equity Plan [Member]
Stock Options and Warrants [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	6,611,480	4,427,234
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 6.82	$ 9.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 4 months 10 days	6 years 11 months 5 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	3,036,688
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares	$ 3.23
Stock Options Exercised	0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ / shares	$ 0
Stock Options Expired	(370,588)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price | $ / shares	$ 5.32
Stock Options Forfeited	(481,854)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | $ / shares	$ 7.34
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	6,362,987
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 6.94
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	7 years 3 months 11 days
Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest	1 year 4 months 21 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	4,685,074
Weighted average estimated fair value of shares granted | $ / shares	$ 7.91
Options, Vested, weighted Average Remaining Contractual Term	6 years 8 months 9 days

Shareholders' Equity Restricted

Shareholders' Equity Restricted Stock (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	811,835	708,706
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 2,367,500	$ 4,964,000
weighted average estimated fair value of restricted stock	$ 3.10	$ 7

Share-Based Compensation Share-

Share-Based Compensation Share-Based Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 436,500	$ 3,287,900	$ 8,568,500	$ 8,941,500
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	3,898,600		$ 3,898,600
Expected weighted-average period in years of compensation cost to be recognized			3 years 3 months 7 days
Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 0		$ 0
Expected weighted-average period in years of compensation cost to be recognized
Total fair value of shares vested			$ 0	15,300
Weighted average estimated fair value of shares granted	$ 0		$ 0		$ 0
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average estimated fair value of shares granted	$ 2.10		$ 2.10		$ 4.67
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 336,500		$ 336,500
Expected weighted-average period in years of compensation cost to be recognized			2 years 8 months 1 day
Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	14,400	55,900	$ 509,500	292,600
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	115,900	515,700	1,642,800	1,364,200
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 306,200	$ 2,716,300	6,416,200	7,284,700
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested			$ 5,303,900	$ 4,141,600

Research Funding - (Details)

Research Funding - (Details) - Additional Funding Agreement Terms [Member] - Phase 3 Intus Study [Member] - USD ($)	1 Months Ended
	Jun. 30, 2015	Sep. 30, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research funding, award amount		$ 17,725,734
Project initiation payment	$ 3,000,000
Future operational milestone payments	$ 14,725,734

Income Taxes Net Operating Loss

Income Taxes Net Operating Loss Carry Forward (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards					$ 177,200,000
Deferred Tax Liabilities, Net, Noncurrent	$ 14,566,093		$ 14,566,093		$ 18,176,190
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	0	$ 0	9,400,000	$ 0
Deferred Tax Liabilities, Deferred Expense	$ (3,700,000)		$ (3,700,000)

Commitments and Contingencies58

Commitments and Contingencies (Details)	Feb. 19, 2015USD ($)ft²renewal_term	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)
Operating Leases, Future Minimum Payments Due [Abstract]
2,015		$ 492,800		$ 492,800
2,016		2,062,000		2,062,000
2,017		1,863,800		1,863,800
2,018		1,034,800		1,034,800
2019 and thereafter		1,949,600		1,949,600
Total minimum lease payments		7,403,000		7,403,000
Operating lease expense		400,000	$ 400,000	1,200,000	$ 900,000
NEW JERSEY
Operating Leased Assets [Line Items]
Operating lease, rentable space | ft²	18,000
Operating leases, monthly rental payments	$ 25,000
Operating leases, number of renewal terms | renewal_term	2
Lessee leasing arrangements, operating leases, renewal term	5 years
Proceeds from lease assignment	$ 580,000
Security deposit liability		$ 115,000		$ 115,000

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - Aspire Capital Purchase Agreement [Member]	1 Months Ended
	Nov. 30, 2015USD ($)shares
Subsequent Event [Line Items]
Purchase Commitment, Remaining Minimum Amount Committed | $	$ 30,000,000
Purchase Commitment, Maximum Amount Committed, Shares	11,019,276
Term of agreement in months	24 months
Stock Issued During Period, Shares, Other	842,696

Uncategorized Items - clbs-2015

Label	Element	Value
Stock Issued During Period, Value, Warrant Exercises	clbs_StockIssuedDuringPeriodValueWarrantExercises	$ 1,720,725
Stock Issued During Period, Value, Acquisitions	us-gaap_StockIssuedDuringPeriodValueAcquisitions	21,600,351
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation	8,941,452
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	112
AOCI Attributable to Parent [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	112
Additional Paid-in Capital [Member]
Stock Issued During Period, Value, Warrant Exercises	clbs_StockIssuedDuringPeriodValueWarrantExercises	1,720,392
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	11,273,259
Stock Issued During Period, Value, Acquisitions	us-gaap_StockIssuedDuringPeriodValueAcquisitions	21,595,021
Change in Ownership in Subsidiary	clbs_ChangeinOwnershipinSubsidiary	(86,617)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	299,594,525
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	343,308,264
Proceeds from Stock Options Exercised	us-gaap_ProceedsFromStockOptionsExercised	270,959
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation	8,940,725
Common Stock [Member]
Stock Issued During Period, Value, Warrant Exercises	clbs_StockIssuedDuringPeriodValueWarrantExercises	$ 333
Stock Issued During Period, Shares, New Issues	us-gaap_StockIssuedDuringPeriodSharesNewIssues	1,850,081
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	$ 1,850
Stock Issued During Period, Value, Acquisitions	us-gaap_StockIssuedDuringPeriodValueAcquisitions	$ 5,330
Stock Issued During Period, Shares, Warrants Exercised	clbs_StockIssuedDuringPeriodSharesWarrantsExercised	333,250
Shares, Outstanding	us-gaap_SharesOutstanding	27,196,537
Shares, Outstanding	us-gaap_SharesOutstanding	35,485,523
Proceeds from option exercises, shares	clbs_Proceedsfromoptionexercisesshares	48,987
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	$ 27,197
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	35,486
Proceeds from Stock Options Exercised	us-gaap_ProceedsFromStockOptionsExercised	$ 49
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures	us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation	727,158
Stock Issued During Period, Shares, Acquisitions	us-gaap_StockIssuedDuringPeriodSharesAcquisitions	5,329,510
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation	$ 727
Noncontrolling Interest [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	(516,040)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	(944,300)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	us-gaap_ProfitLoss	(514,877)
Parent [Member]
Stock Issued During Period, Value, Warrant Exercises	clbs_StockIssuedDuringPeriodValueWarrantExercises	1,720,725
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	11,275,109
Stock Issued During Period, Value, Acquisitions	us-gaap_StockIssuedDuringPeriodValueAcquisitions	21,600,351
Change in Ownership in Subsidiary	clbs_ChangeinOwnershipinSubsidiary	(86,617)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	62,542,475
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	63,003,272
Proceeds from Stock Options Exercised	us-gaap_ProceedsFromStockOptionsExercised	271,008
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation	8,941,452
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	us-gaap_ProfitLoss	(43,261,343)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	112
Retained Earnings [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	(236,373,605)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	(279,634,948)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	us-gaap_ProfitLoss	(43,261,343)
Treasury Stock [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	(705,742)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	$ (705,742)
Series B Preferred Stock [Member] | Preferred Stock [Member]
Shares, Outstanding	us-gaap_SharesOutstanding	10,000
Shares, Outstanding	us-gaap_SharesOutstanding	10,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	$ 100
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	$ 100